Immunotherapy of cancer with genetically modified tumor vaccines

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Distant metastasis is the major cause for therapeutic failures in clinical oncology. Active immunotherapy in the adjuvant setting of patients with low tumor volume would contribute to further reduction of the remaining tumor and establish long-lasting immunity that could protect the patient from recurrence of disease. Studies employing rodent tumor models with little or no intrinsic immunogenicity have shown that genetically modified tumor cell preparations consisting of irradiated tumor cells transduced with and expressing cytokines, such as interleukin-2 (IL-2), IL-6, interferon-γ (IFNγ), or granulocyte-macrophage colony stimulating factor (GM-CSF), or costimulatory molecules, such as B7-I, were capable of inducing the regression of preexisting tumors and cure animals from their disease. Moreover, in some instances, the cured animals have retained immunological memory, as indicated by the fact that animals have resisted a second challenge with the parental tumor cells. Induction of potent immune responses in tumor-bearing animals against nonimmunogenic or weakly immunogenic tumors supports the view that active immunization of cancer patients deserves consideration despite lack of demonstrable immunogenicity in many human tumors.

Original languageEnglish
Pages (from-to)101-107
Number of pages7
JournalSeminars in Oncology
Volume23
Issue number1
StatePublished - Mar 14 1996
Externally publishedYes

Fingerprint

Cancer Vaccines
Immunotherapy
Neoplasms
Immunologic Memory
Active Immunotherapy
Animal Diseases
Medical Oncology
Granulocyte-Macrophage Colony-Stimulating Factor
Tumor Burden
Interferons
Interleukin-2
Immunity
Rodentia
Interleukin-6
Vaccination
Cytokines
Neoplasm Metastasis
Recurrence

ASJC Scopus subject areas

  • Oncology

Cite this

Immunotherapy of cancer with genetically modified tumor vaccines. / Gilboa, Eli.

In: Seminars in Oncology, Vol. 23, No. 1, 14.03.1996, p. 101-107.

Research output: Contribution to journalArticle

@article{5d1d5b502c3646b793b089b475167679,
title = "Immunotherapy of cancer with genetically modified tumor vaccines",
abstract = "Distant metastasis is the major cause for therapeutic failures in clinical oncology. Active immunotherapy in the adjuvant setting of patients with low tumor volume would contribute to further reduction of the remaining tumor and establish long-lasting immunity that could protect the patient from recurrence of disease. Studies employing rodent tumor models with little or no intrinsic immunogenicity have shown that genetically modified tumor cell preparations consisting of irradiated tumor cells transduced with and expressing cytokines, such as interleukin-2 (IL-2), IL-6, interferon-γ (IFNγ), or granulocyte-macrophage colony stimulating factor (GM-CSF), or costimulatory molecules, such as B7-I, were capable of inducing the regression of preexisting tumors and cure animals from their disease. Moreover, in some instances, the cured animals have retained immunological memory, as indicated by the fact that animals have resisted a second challenge with the parental tumor cells. Induction of potent immune responses in tumor-bearing animals against nonimmunogenic or weakly immunogenic tumors supports the view that active immunization of cancer patients deserves consideration despite lack of demonstrable immunogenicity in many human tumors.",
author = "Eli Gilboa",
year = "1996",
month = "3",
day = "14",
language = "English",
volume = "23",
pages = "101--107",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Immunotherapy of cancer with genetically modified tumor vaccines

AU - Gilboa, Eli

PY - 1996/3/14

Y1 - 1996/3/14

N2 - Distant metastasis is the major cause for therapeutic failures in clinical oncology. Active immunotherapy in the adjuvant setting of patients with low tumor volume would contribute to further reduction of the remaining tumor and establish long-lasting immunity that could protect the patient from recurrence of disease. Studies employing rodent tumor models with little or no intrinsic immunogenicity have shown that genetically modified tumor cell preparations consisting of irradiated tumor cells transduced with and expressing cytokines, such as interleukin-2 (IL-2), IL-6, interferon-γ (IFNγ), or granulocyte-macrophage colony stimulating factor (GM-CSF), or costimulatory molecules, such as B7-I, were capable of inducing the regression of preexisting tumors and cure animals from their disease. Moreover, in some instances, the cured animals have retained immunological memory, as indicated by the fact that animals have resisted a second challenge with the parental tumor cells. Induction of potent immune responses in tumor-bearing animals against nonimmunogenic or weakly immunogenic tumors supports the view that active immunization of cancer patients deserves consideration despite lack of demonstrable immunogenicity in many human tumors.

AB - Distant metastasis is the major cause for therapeutic failures in clinical oncology. Active immunotherapy in the adjuvant setting of patients with low tumor volume would contribute to further reduction of the remaining tumor and establish long-lasting immunity that could protect the patient from recurrence of disease. Studies employing rodent tumor models with little or no intrinsic immunogenicity have shown that genetically modified tumor cell preparations consisting of irradiated tumor cells transduced with and expressing cytokines, such as interleukin-2 (IL-2), IL-6, interferon-γ (IFNγ), or granulocyte-macrophage colony stimulating factor (GM-CSF), or costimulatory molecules, such as B7-I, were capable of inducing the regression of preexisting tumors and cure animals from their disease. Moreover, in some instances, the cured animals have retained immunological memory, as indicated by the fact that animals have resisted a second challenge with the parental tumor cells. Induction of potent immune responses in tumor-bearing animals against nonimmunogenic or weakly immunogenic tumors supports the view that active immunization of cancer patients deserves consideration despite lack of demonstrable immunogenicity in many human tumors.

UR - http://www.scopus.com/inward/record.url?scp=0029919272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029919272&partnerID=8YFLogxK

M3 - Article

C2 - 8607020

AN - SCOPUS:0029919272

VL - 23

SP - 101

EP - 107

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 1

ER -